The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Barry D. Kahan

The University of Texas Medical School at Houston

Texas Heart Institute

St. Luke's Episcopal Hospital

Department of Surgery

USA

[email]@uth.tmc.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • The University of Texas Medical School at Houston, Texas Heart Institute, St. Luke's Episcopal Hospital, Department of Surgery, USA. 2011
  • The University of Texas Medical School at Houston, Houston, USA. 2011
  • Division of Immunology and Organ Transplantation, The University of Texas Medical School, Houston, TX 77030, USA. 2001 - 2010
  • University of Texas Medical School at Houston, Department of Surgery, Division of Immunology and Organ Transplantation, Houston, USA. 2002 - 2009

References

  1. Toxicity spectrum of inhibitors of mammalian target of rapamycin in organ transplantation: etiology, pathogenesis and treatment. Kahan, B. Expert. Opin. Drug. Saf (2011) [Pubmed]
  2. Frontiers in immunosuppression. Kahan, B.D. Transplant. Proc. (2011) [Pubmed]
  3. Addition of induction therapy offsets the hazard of marked calcineurin minimization among renal transplant recipients treated with sirolimus. Kahan, B.D., Benavides, C., Schoenberg, L., Podbielski, J., Green, C. Clin. Nephrol. (2010) [Pubmed]
  4. The ruby anniversary: forty years of publication of Transplantation Proceedings - the first decade: the flowering of immunology and immunogenetics. Kahan, B.D. Transplant. Proc. (2009) [Pubmed]
  5. Forty years of publication of transplantation proceedings--the second decade: the cyclosporine revolution. Kahan, B.D. Transplant. Proc. (2009) [Pubmed]
  6. Forty years of publication of transplantation proceedings-the third decade: the expansion of the enterprise. Kahan, B.D. Transplant. Proc. (2009) [Pubmed]
  7. Use of sirolimus to facilitate steroid withdrawal from a cyclosporine regimen. Kahan, B.D., Podbielski, J., Schoenberg, L. Transplant. Proc. (2006) [Pubmed]
  8. Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients. Kahan, B.D., Yakupoglu, Y.K., Schoenberg, L., Knight, R.J., Katz, S.M., Lai, D., Van Buren, C.T. Transplantation (2005) [Pubmed]
  9. Therapeutic drug monitoring of cyclosporine: 20 years of progress. Kahan, B.D. Transplant. Proc. (2004) [Pubmed]
  10. FTY720: from bench to bedside. Kahan, B.D. Transplant. Proc. (2004) [Pubmed]
  11. Phase I and phase II safety and efficacy trial of intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302) for the prevention of acute allograft rejection. Kahan, B.D., Stepkowski, S., Kilic, M., Katz, S.M., Van Buren, C.T., Welsh, M.S., Tami, J.A., Shanahan, W.R. Transplantation (2004) [Pubmed]
  12. Sirolimus-based immunosuppression: present state of the art. Kahan, B.D. J. Nephrol. (2004) [Pubmed]
  13. Individuality: the barrier to optimal immunosuppression. Kahan, B.D. Nat. Rev. Immunol. (2003) [Pubmed]
  14. Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study. Kahan, B.D., Karlix, J.L., Ferguson, R.M., Leichtman, A.B., Mulgaonkar, S., Gonwa, T.A., Skerjanec, A., Schmouder, R.L., Chodoff, L. Transplantation (2003) [Pubmed]
  15. Update on pharmacokinetic/pharmacodynamic studies with FTY720 and sirolimus. Kahan, B.D. Ther. Drug. Monit (2002) [Pubmed]
  16. Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Kahan, B.D., Keown, P., Levy, G.A., Johnston, A. Clin. Ther (2002) [Pubmed]
  17. RAD in de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection. Kahan, B.D., Kaplan, B., Lorber, M.I., Winkler, M., Cambon, N., Boger, R.S. Transplantation (2001) [Pubmed]
  18. Current immunosuppressant regimens: considerations for critical care. Kahan, B.D., Koch, S.M. Curr. Opin. Crit. Care (2001) [Pubmed]
  19. Rapamycin: clinical results and future opportunities. Kahan, B.D., Camardo, J.S. Transplantation (2001) [Pubmed]
  20. Sirolimus: a comprehensive review. Kahan, B.D. Expert. Opin. Pharmacother (2001) [Pubmed]
 
WikiGenes - Universities